

INPLASY

Efficacy and safety of lumateperone in the treatment of schizophrenia and bipolar disorder: a systematic review and meta-analysis

INPLASY202380050

doi: 10.37766/inplasy2023.8.0050

Received: 12 August 2023

Published: 12 August 2023

Yin, ZQ¹; Ren, YB².

Corresponding author:

Ziqian Yin

sudayzq@163.com

Author Affiliation:

First Affiliated Hospital of Soochow University.

ADMINISTRATIVE INFORMATION

Support - National Natural Science Foundation of China.

Review Stage at time of this submission - Completed but not published.

Conflicts of interest - None declared.

INPLASY registration number: INPLASY202380050

Amendments - This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 12 August 2023 and was last updated on 12 August 2023.

INTRODUCTION

Review question / Objective Efficacy and safety of lumateperone in the treatment of schizophrenia and bipolar disorder.

Condition being studied Lumateperone is a new antipsychotic, and there have been numerous randomized controlled trials on lumateperone. Still, there has been no meta-analysis to discuss in detail the efficacy and safety of lumateperone in treating psychiatric disorders. Lumateperone is a new antipsychotic, and there have been numerous randomized controlled trials on lumateperone. Still, there has been no meta-analysis to discuss in detail the efficacy and safety of lumateperone in treating psychiatric disorders. Lumateperone is a new antipsychotic, and there have been numerous randomised efficacy and safety of lumateperone in the treatment of psychiatric disorders.

METHODS

Participant or population diagnosis of schizophrenia or Bipolar disorder according to the Diagnostic and Statistical Manual of Mental Disorder (DSM) 5th edition.

Intervention Lumateperone.

Comparator Placebo.

Study designs to be included Efficacy and safety of lumateperone in the treatment of schizophrenia and bipolar disorder.

Eligibility criteria See the Method in the main text for details.

Information sources We searched Embase, pubmed, and corchane databases for all randomized controlled trials, and analyzed

previous meta-included articles to avoid omissions.

Main outcome(s) Total PANSS, MADRS total score.

Quality assessment / Risk of bias analysis The risk of bias plot for individual studies was assessed with the Review Manager 5.3 software.

Strategy of data synthesis Review Manager 5.3 software was used for all statistical analyses. Continuous and dichotomous variables have been presented as mean difference (MD) and risk ratios (RR) with 95% confidence intervals (CIs).

Subgroup analysis We divide mental illness into schizophrenia and bipolar disorder.

Sensitivity analysis We used the reservation-one method and sequentially eliminated RCTS to measure the heterogeneity of the study.

Country(ies) involved China.

Keywords Lumateperone; Schizophrenia; Bipolar disorder; Systematic review; Meta-analysis.

Contributions of each author

Author 1 - Ziqian Yin.

Email: sudayzq@163.com

Author 2 - Yubo Ren.